Abstract:Dr. Schlemm et al. performed a prespecified analysis of the association of cerebral microbleeds (CMBs) with the treatment effect of IV alteplase vs placebo in the randomized controlled WAKE-UP (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke) trial of patients with acute ischemic stroke with unknown time of symptom onset and diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch on MRI. Among 459 patients available for analysis, there was no evidence of reduced treatment effect of alteplase in the 98 (21.4%) patients who had at least 1 CMB on baseline imaging. However, CMBs were associated with a nonsignificant increased risk of symptomatic intracranial hemorrhage (ICH; 11.2% vs 4.2%; adjusted odds ratio 2.32, 95% CI 0.99–5.43). In response, Drs. Meinel and Seiffge highlight the importance of distinguishing patients with CMBs from cerebral amyloid angiopathy or other cerebral small vessel disease—who have an increased risk of postthrombolysis ICH—from those with other causes of CMBs and other such lesions on susceptibility-weighted imaging, like those seen after valve implantation, extracorporeal membrane oxygenation, or prolonged intensive care unit stay. They also recommend examining the interaction of CMBs and white matter hyperintensities to better elucidate the risk of postthrombolysis hemorrhage. Responding to these comments, the authors note that new CMBs in acute ischemic stroke patients after IV thrombolysis were associated with an increased risk of hemorrhagic complications in prior literature, whereas new CMBs after cardiac surgery were not associated with bleeding risk, suggesting different risk profiles for patients with different causes of acute CMBs—a topic meriting further investigation in histopathology and observational studies. This exchange highlights the challenges of disentangling cause-specific bleeding risks associated with CMBs when examining ICH outcomes in patients undergoing thrombolysis. Dr. Schlemm et al. performed a prespecified analysis of the association of cerebral microbleeds (CMBs) with the treatment effect of IV alteplase vs placebo in the randomized controlled WAKE-UP (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke) trial of patients with acute ischemic stroke with unknown time of symptom onset and diffusion-weighted imaging–fluid-attenuated inversion recovery mismatch on MRI. Among 459 patients available for analysis, there was no evidence of reduced treatment effect of alteplase in the 98 (21.4%) patients who had at least 1 CMB on baseline imaging. However, CMBs were associated with a nonsignificant increased risk of symptomatic intracranial hemorrhage (ICH; 11.2% vs 4.2%; adjusted odds ratio 2.32, 95% CI 0.99–5.43). In response, Drs. Meinel and Seiffge highlight the importance of distinguishing patients with CMBs from cerebral amyloid angiopathy or other cerebral small vessel disease—who have an increased risk of postthrombolysis ICH—from those with other causes of CMBs and other such lesions on susceptibility-weighted imaging, like those seen after valve implantation, extracorporeal membrane oxygenation, or prolonged intensive care unit stay. They also recommend examining the interaction of CMBs and white matter hyperintensities to better elucidate the risk of postthrombolysis hemorrhage. Responding to these comments, the authors note that new CMBs in acute ischemic stroke patients after IV thrombolysis were associated with an increased risk of hemorrhagic complications in prior literature, whereas new CMBs after cardiac surgery were not associated with bleeding risk, suggesting different risk profiles for patients with different causes of acute CMBs—a topic meriting further investigation in histopathology and observational studies. This exchange highlights the challenges of disentangling cause-specific bleeding risks associated with CMBs when examining ICH outcomes in patients undergoing thrombolysis.

Risk of Intravenous Thrombolysis in Acute Cerebral Infarction with Various Degree of Cerebral Microbleeds by SWI

[Impact of Cerebral Microbleeds on Outcomes of Acute Ischemic Stroke Treated with Intravenous Thrombolysis].

A study on application value of susceptibility weighted imaging combined with platelet distribution width in intravenous thrombolysis for treatment of patients with acute cerebral infarction

[Safety of Intravenous Thrombolysis in Cerebral Microbleeds Patients with Prior Antiplatelet Therapy].

Clinical Outcome in Acute Ischemic Stroke Patients with Microbleeds after Thrombolytic Therapy A Meta-Analysis

Extensive Cerebral Microbleeds Predict Parenchymal Haemorrhage and Poor Outcome after Intravenous Thrombolysis

Microbleeds, Cerebral Hemorrhage, and Functional Outcome After Stroke Thrombolysis.

[Signifiance of Brush Sign on Susceptibility-Weighted Imaging Predicts Hemorrhagic Transformation after Intravenous Thrombolysis in Patients with Acute Ischemic Stroke].

Correlation between antiplatelet therapy in secondary prevention of acute cerebral infarction and cerebral microbleeds: A susceptibility-weighted imaging (SWI) study.

Hemorrhagic risk after intravenous thrombolysis for ischemic stroke in patients with cerebral microbleeds and white matter disease

Alberta stroke programme early CT score on diffusion-weighted imaging and clot burden scoring on MR angiography in the prediction of hemorrhagic transformation after thrombolysis in acute cerebral infarction

The Relationship Between T2 White-Matter Hyperintensities and Hemorrhagic Transformation and Neurological Outcome after Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke

Effect of Bleeding Risk Prediction on Decision Making of Intravenous Thrombolysis Before Thrombectomy: a Subgroup Analysis of DIRECT-MT.

Total Cerebral Small Vessel Disease Score and Cerebral Bleeding Risk in Patients With Acute Stroke Treated With Intravenous Thrombolysis

Number of cerebral microbleeds and risk of intracerebral hemorrhage after intravenous thrombolysis

The Use of Susceptibility-Weighted Imaging to Detect Cerebral Microbleeds after Lacunar Infarction.

The Impact of Cerebral Microbleeds on Intracerebral Hemorrhage and Poor Functional Outcome of Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis: a Systematic Review and Meta-Analysis

Correlation study and clinical value analysis between cerebral microbleeds and white matter hyperintensity with high-field susceptibility-weighted imaging

[Efficacy of intravenous thrombolysis for acute severe cerebral infarction and risk factors of poor prognosis: a randomized controlled trial in 152 cases]

Editors' Note: Cerebral Microbleeds and Treatment Effect of Intravenous Thrombolysis in Acute Stroke: An Analysis of the WAKE-UP Randomized Clinical Trial

Clinical application value of magnetic susceptibility-weighted imaging in early cerebral infarction